MetaCap

CAMP4 Therapeutics (CAMP) vs Rocket Pharmaceuticals (RCKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CAMP4 Therapeutics (CAMP) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 30.7% versus a loss of 33.4%. CAMP4 Therapeutics is the larger company by market cap ($237.8 million vs $217.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAMP+30.69%RCKT-33.45%
+155%+56%-42%
Nov 21, 20251 yearNov 20, 2026
CAMP-64.65%RCKT-88.60%
+15%-39%-94%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAMP versus RCKT key metrics
MetricCAMPRCKT
Share price$3.79$1.95
Market cap$237.84M$217.74M
1-day change-5.25%-7.58%
YTD return-38.17%-44.44%
1-year return+30.69%-33.45%
5-year return—-91.76%
EPS (TTM)$-2.11$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.50M$0
Revenue growth (YoY)+436.50%—
Net income (latest FY)$-80.40M$-223.12M
Operating margin-1502.43%—
Net margin-2298.54%—
52-week high$7.75$5.45
52-week low$2.90$1.94
Distance from 52-week high-51.10%-64.22%
Analyst consensusstrong_buybuy
Avg. price target upside+169.66%+326.15%
Average volume238.88K1.90M
Shares outstanding62.75M111.66M
Employees48202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAMP has outperformed RCKT by 64.1 percentage points over the past year.

About CAMP4 Therapeutics

CAMP stock →

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Rocket Pharmaceuticals

RCKT stock →

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees

CAMP vs RCKT FAQ

Which is bigger, CAMP4 Therapeutics or Rocket Pharmaceuticals?

CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $237.84M compared with $217.74M for Rocket Pharmaceuticals (RCKT).

Which stock has performed better over the past year, CAMP or RCKT?

CAMP returned +30.69% over the past 12 months, compared with -33.45% for RCKT (price return, excluding dividends). Past performance does not predict future results.

Are CAMP4 Therapeutics and Rocket Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons